Garadacimab

加达西单抗

Report date: 2026/04/16 20:00:17
First In Class

Base Information

Drug NameGaradacimab
Drug Alias Namegaradacimab-gxiiAndembryCSL-312
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCoagulation factor XII inhibitors
TargetsCoagulation factor XII
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)ThrombosisAngioedemas, Hereditary +[4] 
Global Approved IndicationsAngioedemas, Hereditary
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2025/01/24
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesCsl Behring Llc
China Registration ClassN/A

Develop Information

Active CompaniesCsl Behring AgCsl Behring KkCsl Behring +[4] 
Inactive CompaniesN/A
Active IndicationsAngioedemas, HereditaryIdiopathic Pulmonary Fibrosis
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Thrombosis

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG